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Mono- or combine immunosuppressants are commonly used for psoriasis; however the side eﬀect caused by potent systemic
immunosuppressants frequently incurred; moreover the inﬂammation ﬂares up shortly after immunosuppressants are discon-
tinued. An alternative nonimmunosuppressive therapy was introduced to psoriasis subjects. A retrospective observational study
consisted of 1583 psoriasis patients who were treated with Herose Psoria capsule 1440mg three times daily at two clinical centres,
one in China, the other in Singapore, from 1 January 2000 to 1 January 2011. Psoriasis lesion evolution was photographed
at monthly visit, and eﬃcacy and safety were assessed using psoriasis area severity index PASI score grading, renal and liver
function testing, and adverse event reporting and supplemented by information obtained during targeted telephone interviews.
The eﬀectiveness of Herose on psoriasis was inversely associated to prior immunosuppressants exposure (r = 0.9154), signiﬁcant
improvements occurred in non-immunosuppressants subjects, and complete clearance was achieved in 8 months (87.5%, 14 of
16); the wavelike evolution of psoriatic lesion appeared in prior immunosuppressants subjects.
1.Introduction
Psoriasis is quite common; its prevalence ranges from 0.6%
to 4.8% and shows a wide variability among ethnic groups
[1].Theestimatedprevalenceofpsoriasisis0.123%inChina,
and there have been more than 3 million cases reported since
1984 [2]. In Singapore, psoriasis aﬀects 1% to 2% of the
population.Clinicalmanifestationofpsoriasisisheterogene-
ous, ranging from limited to extensive. Guttate psoriasis is
often a self-limited disease, lasting from 12 to 16 weeks
withouttreatment[3].Ithasbeenestimatedthatone-thirdto
two-thirds of these patients later develop the chronic plaque
type of psoriasis [4]; however, chronic plaque psoriasis is in
most cases a lifelong disease and reported to wax and wane
over time with episode of remissions and exacerbations [5],
manifesting at unpredictable intervals. Erythrodermic and
generalized pustular psoriasis have a poorer prognosis, with
the disease tending to be severe and persistent [3].
Dermatological pathogenesis and medicine are ever-
changing science. As new research and clinical experience
broaden our knowledge, changes in treatment and drug
therapy are required, previously psoriasis had been viewed as
primarily a disease of hyperproliferation, and more recently
it has come to be regarded as an autoimmune-mediated
disease; hence the conventional systemic immunosuppres-
sive (Corticosteroids, PUVA, MTX, cyclosporine) therapy
started shifting to immune system partial (T cell, cytokines,
chemokines, proteases, integrins) suppressive therapy, and
alefacept and efalizumab targeted anti-inﬂammatory strate-
gies are being tested with T-cell inhibitors. Adalimumab,
certolizumab, etanercept, inﬂiximab, and golimumab tumor
necrosis factor (TNF) antagonists are approved; ustek-
inumab [6–8] and briakinumab [9] are inhibiting inter-
leukins (IL) 12 and 23; clinical trials are underway of a few
drugs that inhibit IL-17 and/or L-17 receptor. Another trial
is studying an IL-22 blocking agent; meanwhile resveratrol,
vb-201, apremilast, and tasocitinib are being studied as oral
inhibitors of inﬂammatory cytokines.
The decision to implement therapy with immunosup-
pressants must be derived from a precise understanding of
these agents and the often formidable adverse reactions that
accompany their use (efalizumab which inhibit CD11a has2 Dermatology Research and Practice
Table 1: Herose Psoria capsule∗ ingredients.
Ingredient Amount (mg)
Rhizoma Zingiberis (Gan Jiang), ginger 429mg
Radix Paeoniae Alba (Bai Shao), white peony root 156mg
Radix Astragali (Huang Qi), astragalus root 313mg
Radix Salviae Miltiorrhizae (Dan Shen), root of red-rooted salvia 556mg
Ramulus Cinnamomi (Gui Zhi), cassia twig 299mg
Semen Coicis ( Y iR e n ) ,J o b ’ st e a r ss e e d 538mg
Radix Codonopsis pilosula (Dang Shen), root of Codonopsis pilosula 63mg
∗Each capsule consists of 360mg extract equivalent to 2354mg raw herbs.
been associated with PML progressive multifocal leukoen-
cephalopathy [10]), for inﬂammatory and autoimmune-
related skin disorders as psoriasis which is not life-threat-
ening; it is incumbent on the treating physicians to deter-
mine that immunosuppressants are the appropriate form of
treatment. Long-term remission and preventing recurrence
werethepriorityinpsoriasismanagement;thisobservational
study was to describe the therapeutic response, tolerance,
and safety of herose psoria capsule, a nonimmunosuppres-
sive approach, in psoriasis patients.
2.MaterialsandMethods
We conducted a retrospective observational study and anal-
ysed 1583 consecutive psoriasis patients who were given
Herose Psoria capsule at two clinical centres, Tang Jinghua
Clinical Centre China and Herose Clinical Centre Singapore,
between 1 January 2000 and 1 January 2011. The medical
records and photodocumentation were reviewed.
To complete mean 5 years of continuous followup, we
excluded patients who initialized herose psoria therapy after
1 January 2008; the patients who were lost to followup or
dropped out for various reason were included; ultimately
1215 patients were included in this study. We collected the
following information: age; psoriasis area severity index
(PASI), prior psoriasis duration, dose and duration of prior
treatment, comorbidities and concurrent treatments, thera-
peutic beneﬁt, adverse events, and duration of followup.
Patients were informed that herose psoria [11, 12]c a p -
sule (HerosePharma, Singapore) (Table 1)w a sp r e s c r i b e d
1440mg three times daily, and they gave written consent for
its use. Treatment arm, herose psoria (Table 1) capsule is a
botanical compound formulated to stimulate the yang com-
ponent of the human body and was approved as a Chinese
Proprietary Medicine (CPM) by Health Science Authority
(HSA)ofSingaporetotreatpsoriasis,manufacturedbyGMP
factory in Singapore. Before starting herose, each patient
underwent photograph taking, psoriasis area and severity
index PASI grading; the blood test (liver function and renal
function) was ordered for patients who were treated with
systemic immunosuppressants previously.
During the study period, no other antipsoriatic treat-
ment modalities, apart from herose psoria, were given, pa-
tients were advised to use topical Johnson & Johnson
lotion or Vaseline to relieve skin dryness, antihistamine for
itchiness, and antibiotics if required for secondary infec-
tion, psoriatic arthritis patiens were administrated with
nonsteroid anti-inﬂammatory drugs (NSAIDs) by their
rheumatologist, hypertension and hyperlipidaemia were
given antihypertensive drugs and antihyperglycemic drugs
by their cardioangiologist, diabetes and gastritis continued
their antidiabetic medications and antigastritis or antiulcer
agents, and asthma and eczema were advised non-steroids
medications.
Patients discontinued immunosuppressants therapy 7
days before initiating herose and were clinically monitored
on a monthly basis, digital photographs were taken at each
follow-up visit, and physicians reviewed photographs taken
before and after treatment, when available. The eﬃcacy
parameters included PASI with photograph comparison and
the Physician Global Assessment (PGA) of the therapeutic
response. The main criteria assessed were as follows: time to
receive PASI 75% improvements; time to reach full clearance
after starting heroes. Patients who received full clearance
were reassessed for relapse via telephone followup annually
till 1 January 2011. Adverse eﬀects were assessed via clinical
reporting, examination, lab studies.
Descriptive statistics were calculated using numbers with
means, percentages, and range. To identify potential predic-
tors of a good clinical response, we evaluated correlation
coeﬃcient between time to reach PASI75 improvement to
cumulated previous immunosuppressants treatments, and
psoriasis duration before herose treatment, and initial
PASI score at herose treatment, and patients’ age. Time
serial psoriasis lesion evolution curve of both prior non-
immunosuppressive treatment group and prior immuno-
suppressive treatment group was presented. Data were
analysed and two-way graphs and matrix were produced by
using STATA software (StataCorp, Tx).
3. Results and Discussion
A total of 1583 consecutive psoriasis medical records were
collected at two clinical centers, one in China and the other
inSingapore, between1January2000 and 1January2011. To
complete mean 5 years of continuous followup, ultimately
1215 patients were included in this study (Figure 1); of
these patients with prior non-immunosuppressive therapy
(n = 16), 14 patients (87.5%) reached complete clearance
in 8 months thereafter with mean 30 months of subsequentDermatology Research and Practice 3
Patients’ data screened from 1 January 2000 to 1 January 2011
n = 1583
Patients initiated treatment between 1 January 2000 and
1 January 2008 with followup till 1 January 2011
n = 1215
Patients with prior non
immunosuppressants therapy
n = 16
Patients with prior
immunosuppressants therapy
n = 1199
• 2 discontinued at month 4 due
to no clinical response
(12.5%)
￿ 14 reached complete
clearance at month 8 (87.5%)
￿ Mean subsequent followup
30 months after clearance till
1 January 2011
￿ 3 discontinued due to plan of
pregnancy (0.3%)
￿ 1020 dropout due to 
unsatisfactory therapeutic
eﬀect (85%)
￿ 176 completed the therapy
and reached PASI75
improvement in 60 months
(14.7%)
Figure 1: Flowchart and outcomes of the study.
followup; of those patients with prior immunosuppressive
therapy (n = 1199), 176 patients (14.7%) completed therapy
and achieved PASI75 in 60 months treatment. The main
baseline characteristics and 60 months of screening of 1215
study subjects are summarized in Table 2. We found that
141 (11.6%), 103 (8.5%), 47 (3.9%), 123 (10.1%), 19
(1.6%), 28 (2.3%), 19 (1.6%), 18 (1.5%), and 18 (1.5%) of
patients with psoriasis had comorbidities of hypertension,
hyperlipidaemia, asthma, arthritis, hepatitis B, diabetes, gas-
tritis, eczema, and gout, respectively, in which some of pa-
tients received more than one type of comorbidities. At the
baseline,theaverageofpatients’ageisat42.4years(range,18
years to 71 years), the average of psoriasis duration is 9.7
y e a r sw i t hr a n g ef r o m1y e a rt o3 9y e a r s ,a n dt h em e a n
PASI is 28.9 with range from 3.6 to 68. Of the 1215 pa-
tients with psoriasis, only 16 (1.3%) received prior non-
immunosuppressant therapy, and 1199 (98.7%) had previ-
ous immunosuppressive treatment. Table 2 reveals that 588
(48.4%) received less than 6 months of cumulated dose of
prior immunosuppressants, and 332 (27.3%), 170 (14%), 33
(2.7%), and 76 (6.3%) received cumulated doses of prior
immunosuppressants 6–12 months, 12–24 months, 24–36
months, and more than 36 months, respectively.
Table 3 shows the prior immunosuppressant modalities
for psoriasis patients in this study, we also found that almost
all patients with psoriasis had used topical steroids therapy
(98.7%), and 46.6% had received systemic steroid (orally
P.O. or intravenously I.V.) therapy. Majority of Asia psoriasis
subjects had taken traditional herbal immunosuppressive
decoction/powder medication (71.5%), and the commonly
used herbal immunosuppressanst are listed in Table 3.
The patients with prior non-immunosuppressants ther-
apy had shown signiﬁcant response to herose, with 87.5%
(14/16) experiencing PASI75 improvement at month 4.5,
and received complete clearance in month 8 (Figure 2); in
comparison with patients with prior immunosuppressants
therapy, the absolute dropout rate is much lower at 12.5%
(2/16) in 60-month study compared with prior immunosup-
pressants group which is 29% (347/1199), 57% (687/1199),
64% (764/1199), 72% (858/1199), 83% (995/1199), and 85%
(1023/1199) at month 1, month 3, month 6, month 12,
month 18, and month 60, respectively. All 1199 patients with
prior immunosuppressants treatment experienced mean
110% (range, from 55% to 240%) worsening of PASI score
relative to baseline value during the study (Figure 3), which
was the immunosuppressants withdrawal syndrome [33–37]
of psoriasis ﬂare. At the end point, 14 (7.4%), 9 (4.5%),
1 (0.6%), 16 (8.5%), 1 (0.6%), and 1 (0.2%) psoriasis
patients with comorbidities of hypertension, hyperlipi-
daemia, asthma, arthritis, hepatitis B, and eczema completed
studyandachievedPhysicianGlobalAssessment(PGA)score
of “minimal” at month 60.
The C-reactive protein (CRP) and erythrocyte sedimen-
tation rate (ESR) are often elevated in patients with psoriasis4 Dermatology Research and Practice
Table 2: Baseline characteristics and follow-up data of the 1215 psoriasis patients with herose treatment.
Baseline Month 1 Month 3 Month 6 Month 12 Month 18 Month 60
n = 1215 n = 868 n = 528 n = 449 n = 355 n = 218 n = 190
Age (yr) at herose initiation,
mean (range) 42.4 (18–71) 41.7 (19–70) 41.7 (22–68) 42 (22–68) 41.7 (22–68) 41.9 (22–66) 41.5 (22–62)
Psoriasis duration (yr) before
herose treatment, mean (range) 9.7 (1–39) 9.5 (1–39) 9.6 (1–39) 9.4 (1–39) 9.5 (1–39) 9.4 (1–25) 8.6 (1–25)
PASI score, mean (range) 28.9 (3.6–68) 39.7 (6.2–70) 45.2 (9.4–72) 38.4 (0–70) 29 (0–63.1) 32.7 (0–58.3) 1.4 (0–16.4)
Cumulated previous
immunosuppressants treatment
(mo), n (%)
Null 16 (1.3%) 16 (1.8%) 16 (3%) 14 (3.1%) 14 (3.9%) 14 (6.4%) 14 (7.4%)
<6 months 588 (48.4%) 430 (49.5%) 268 (50.8%) 227 (50.6%) 164 (46.2%) 101 (46.3%) 95 (50%)
6–12 months 332 (27.3%) 231 (26.6%) 135 (25.6%) 116 (25.8%) 95 (26.8%) 54 (24.8%) 68 (35.8%)
12–24 months 170 (14%) 115 (13.2%) 79 (15%) 73 (16.3%) 63 (17.7%) 38 (17.4%) 13 (6.8%)
24–36 months 33 (2.7%) 27 (3.1%) 6 (1.1%) 0 0 0 0
>36 months 76 (6.3%) 49 (5.6%) 24 (4.5%) 19 (4.2%) 19 (5.4%) 11 (5.1%) 0
Past illness, percentage
Hypertension 141 (11.6%) 14 (7.4%)
Hyperlipidemia 103 (8.5%) 9 (4.5%)
Asthma 47 (3.9%) 1 (0.6%)
Arthritis 123 (10.1%) 16 (8.5%)
Hepetitis B 19 (1.6%) 1 (0.6%)
Diabetes 28 (2.3%) 0
Gastritis 19 (1.6%) 0
Eczema 18 (1.5%) 1 (0.6%)
Gout 18 (1.5%) 0
Table 3: Immunosuppressants modalities in China and Singapore patients with psoriasis.
Immunosuppressants modalities in China and Singapore patients with psoriasis %
Topical
Corticosteroids 98.7%
Calcipotriol 30.2%
Retinoid 11.4%
Tacrolimus 3.8%
Systemic
Systemic glucocorticoid 46.6%
UVB or PUVA 21.5%
Methotrexate 15.7%
Cyclosporine 5.2%
Azathioprine 0.2%
Hydroxyurea 0.2%
Herbal decoction
Glycyrrhiza (Gan Cao), Licorice [13–15] 71.5%
Lonicera (Jin Yin Hua), Honeysuckle 71.5%
Dictamnus (Bai Xian Pi), Burning Bush [16] 71.5%
Cryptotympana (Chan Tui), Cicada Slough 71.5%
Tripterygium (Lei Gong Teng), Threewingnut [17–20] 14.5%
Sophora (Ku Shen), Flavescent Sophora [15, 21, 22] 62.4%
Prunella (Xia Ku Cao), Self Heal [23] 71.5%
Curcuma (Jiang Huang, Yu Jin), Turmeric [24–27] 71.5%
Bupleurum (Chai Hu), Thorowax [28–30] 23.0%
Cordyceps sinensis (Dong Chong Xia Cao) [31, 32] 35.4%Dermatology Research and Practice 5
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Figure 2: Psoriasis area and severity index scores and percentage change in PASI from the baseline screening to month 8 in 16 psoriasis
patients without prior immunosuppressive therapy. After the start of herose, the severity of disease subsided gradually, 14 of 16 patients
receivedcompleteclearancein8months,themeantreatmentperiodtoachievePASI75improvementis4.5months,andthemeansubsequent
follow-up period after clearance is 30 months; 2 of 16 patients had no clinical response and ceased the medication at month 4 and month 5,
respectively.
or psoriatic arthritis. Pertaining to the 176 patients with
prior immunosuppressants treatment who completed this
study, median CRP concentration and ESR are 1.5mg/L
and 24mm/hr, respectively, at baseline. CRP concentra-
tions declined during the 60-month study, with a median
reduction from initial 1.5mg/L to ﬁnal value of 0.5mg/L
for psoriasis without arthritis (160/176) and 0.8mg/L for
psoriasis arthritis (16/176). ESR declined to normal range
concurrently along with CRP, with ﬁnal value of 11mm/hr
(age <50 years) and 15mm/hr (age >50 years).
Elevated liver function test occurred in 231 patients
with prior immunosuppressants therapy before initiating
herose, median serum alanine aminotransferase (ALT) and
aspartate aminotransferase (AST) levels were at 65U/L and
56U/L,respectively,atbaseline,anditappearstoberesulting
from prior methotrexate therapy which had been associated
with both acute and chronic hepatotoxicity. The median
AL T and AST declined to 55U/L and 48U/L, 40U/L and
30U/L at month 5 and month 10, respectively, during
the study. Elevation of blood urea nitrogen (BUN) and
serum creatinine was observed in 65 patients with prior
immunosuppressantstherapy;itappearstoberesultingfrom
prior cyclosporine therapy, and it declined to 18mg/dL and
1.0mg/dL at month 5 after discontinue of the drug.
During the study, no systemic toxicities were uncovered
by laboratory test, and no serious adverse eﬀects were seen.
The enzymes 5-lipoxygenase and elastase are therapeutic
targets in dermatological disorders such as psoriasis. Astra-
galus membranaceus inhibited 5-lipoxygenase with IC50
values of 141 microg mL(−1) [38]. The cellular immunity
(T-lymphocyte subsets) study on one of herose ingredient
astragali showed that the CD4 level and CD4/CD8 ratio
increased levels of sIL-2R, and IgG and IgA lowered sig-
niﬁcantly [39]. Astragaloside Intravenous (ASI) increased
T, B lymphocyte proliferation and antibody production in
vivo and in vitro, but inhibited productions of IL-1 and
TNF-alpha from peritoneal macrophages in vitro [40]. The
haematology study of herose also showed that CD4 level
increased by 20% and CD4/CD8 ratio increased by 20% in
the immune-suppressed patient. The activation of nuclear
transcription factor kappaB has now been linked with a
variety of inﬂammatory diseases, including psoriasis and
AIDS. Extensive research in the last few years has shown
that the pathway that activates this transcription factor can
be interrupted by phytochemicals ginger (gingerol) [41].
The zingiberene and zingerone, the extraction of ginger,
promote adrenal medulla to double-release catecholamine
and has marked anti-inﬂammatory eﬀects [42, 43]. The6 Dermatology Research and Practice
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Figure 3: Psoriasis area and Severity index scores and percentage change in PASI from the baseline screening to month 60 in psoriasis
patients with prior immunosuppressive therapy. 176 of 1199 patients with prior immunosuppressants therapy completed the study and
reached PASI75 improvement in 60 months treatment and followup. The two-way graphs of 176 patients were generated, to save the space, a
random selection of 30 of 176 patients was presented herewith on the above twoway graphs, patients underwent 7-day washouts of previous
immunosuppressant treatments before starting herose, the severity of diseases ﬂared up to a high point initially, and all patients (1199)
experienced mean 110% (range from 55% to 240%) worsening of PASI score relative to baseline, but henceforth progressively tapered down
when immunosuppressant withdrawal syndrome had subsided.
Cinnamomum and Codonopsis pilosula have stimulatory
eﬀect on immunoglobulin (Ig) production by B cells and
interleukin IL-1 production by monocytes in vitro [44].
Dansheng has action of promoting blood circulation and
relieving blood stasis, resolving swelling [45]. The basic
ingredient tanshinone can reduce aggregation of platelets,
improve microcirculation and also has bacteriostatic and
anti-inﬂammatory eﬀects [46, 47]. White peony root lowers
blood pressure and has anticonvulsion, anti-inﬂammation,
and ulcer-prevention eﬀects [48]; the in vitro testing has
revealed that this herb possesses potent inhibitory activity
against Shigella dysenteriae, Salmonella typhi,a n dStaphy-
lococcus aureaus, and inﬂuenza virus to certain extent as
well [47, 49]. The seeds of Jobstears act on spleen, stomach,
and lung channels to remove dampness, tonify spleen,
eliminate heat, and has sedative, analgesic, and antipyretic
coixenolide eﬀects [50]; the ethanol extraction of the herb is
an eﬀective therapy for Ehrlich ascites sarcoma and prolongs
the lifespan of cancerous rats [51]. As the components of
herose psoria do not suppress the immune system cells to
achieve anti-inﬂammatory eﬀect, it is unknown why non-
immunosuppressant approach worked on psoriasis and why
herose had a better eﬀective therapeutic approach in the
patients with prior non-immunosuppressants treatment
than those with prior immunosuppressants.
Singapore Health Science Authority (HSA) required
manufacturers with Good Manufacturing Practices (GMPs)
to register herbal medicine and to license it as Chinese
Proprietary Medicine (CPM) that complies with toxic heavy
metals limits and microbial limits; companies need to carry
out postmarketing surveillance and report serious adverse
events. The Medicine Act and Regulations of Singapore
require CPMs be properly labeled, free of adulterants, pro-
duction controls, and appropriate documentation. The
herbal medicine, like herose, uses plants extract to treat
disease, either a single herb or mixture of diﬀerent herbs.
Unlike conventional drugs, in which the active substance
is extracted from the chemicals, herbal medicines usually
make use of the herb in its partial or whole form, herbs are
complex substances with dozens or hundreds of chemical
constituents, and often it is unclear which of these chemicals
play an important role in the herb’s pharmacologic activ-
ity; therefore determining which ingredient or ingredients
should be considered active and thus would be subject to
standardization can be diﬃcult.
To establish potential predictors of a good clinical
response with herose treatment, we tested correlation coef-
ﬁcient between months to achieve PASI75 and patients age,
psoriasis duration, initial PASI score (Figure 4), and we
found that months required reaching 75% reduction in PASI
score are highly related with cumulated prior immunosup-
pressive treatment (r = 0.9154); however the correlations to
other factors, patients age, psoriasis duration, and initial
PASI score, are weak (r = 0.1295, 0.4400, 0.1783, resp.).
The time to reach PASI75 and clinical clearance signiﬁcantly
depends on the dosage and potency of cumulated prior
immunosuppressive therapy (Figure 4).
During the study, we also observed that visible recovery
began form head region downwards gradually spreading
towards lower limbs in all responded patients with prior8 Dermatology Research and Practice
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Figure 4: Correlation between months required reaching 75% reduction in PASI score and cumulated prior immunosuppressive treatment
is strong (r = 0.9154) however the correlations to other factors, patients age, psoriasis duration, and initial PASI score, are weak (r =
0.1295, 0.4400, 0.1783, resp.). The time to reach PASI75 and clinical clearance signiﬁcantly depends on the dosage and potency of the
immunosuppressants that the patients had formerly consumed.
(a) (b) (c) (d) (e)
Figure 5: Progression of psoriasis improvement in patients with prior non-immunosuppressants therapy. Photographs taken before
treatment, sharply marginated erythematous papule with a silvery-white scale (a). Existing psoriatic plaques developed and spread in sizes at
month 1 (b). Flakes exfoliated from psoriatic lesion reduced in size, existing psoriatic plaques ceased further growth, and psoriatic plaques
became thinner at month 2 (c). Existing psoriatic plaques eradicated and subsided lesion areas became paler than normal skin in color,
similar to that in vitiligo. Notable improvement of PASI75 was achieved at month 3 (d). Skin areas with the vitiligo coloration took on a
natural skin tone, and full clearance was received at month 5 (e).
non-immunosuppressants therapy, complete clearance was
within 8 months (Figure 2), when existing psoriatic plaques
were eradicated, the subsided lesion areas became paler than
normal skin color similar to vitiligo (Figure 5)c o m p a r e dt o
the normal surrounding skin, and the skin areas with vitiligo
colorationevolvedtoanaturalskintonewithinthreemonths
without further medication (Figure 5). However in the
patientswithpriorimmunosuppressivetherapy,weobserved
the improvement began from the lower limbs upwards
gradually spreading towards upper trunks (Figure 6), or
improvement began from the center of the psoriatic plaques
with remission expanding towards the periphery of theDermatology Research and Practice 9
(a) (b) (c) (d)
(e) (f) (g) (h)
(i) (j) (k) (l)
Figure 6:Evolutionofpsoriasislesioninpatientswithpriorimmunosuppressantstherapy.(a)Month0.Photographbeforeinitiatingherose.
(b) Month 1. (c) Month 2. (d) Month 3. (e) Month 4. (f) Month 5. (g) Month 6. (h) Month 9. (i) Month 12. (j) Month 18. (k) Month 26. (l)
Month 32. Patient experienced 200% worsening of PASI score from month 1 (b) to month 6 (g) relative to baseline value (a), which was the
immunosuppressants withdrawal syndrome, the severity of psoriasis ﬂared up to a high point, but henceforth progressively tapered down,
ﬂakes exfoliated from psoriatic lesion reduced in size and ﬁner ﬂakes shed oﬀ, psoriatic plaques became thinner as shown at month 18 (j),
improvement of PASI75 was achieved at month 26 (k), psoriatic plaques eradicated, and the subsided lesion area faded to a greyish colour
(k, l).
psoriatic lesion; the subsided psoriatic plaques and sub-
s i d e dl e s i o na r e at u r nt oag r e y i s hc o l o r( Figure 6) rather
than vitiligo color shown in patients in the prior non-
immunosuppressants group (Figure 5). During the study,
patients with prior immunosuppressant therapy likely start-
edtoexperiencethewavelikeﬂare-upcycle(Figure 3).Symp-
toms of psoriasis which had previously been suppressed by
immunotherapy appeared to resurface with vigor after the
immune system is no longer being curtailed, and over the
time, the ﬂare-up subsided in frequency and intensity in a
wavelike pattern (Figure 3). The time to reach the endpoint
where the wave draws to a null appeared to depend on the
dosage and potency of the immunosuppressants that the
patients had formerly consumed (Figure 4). The interview
with patients uncovered that the wavelike evolution of
immunosuppressants withdrawal syndrome of psoriasis ﬂare
(Figure 3) is the most unsatisﬁed and challenging with them,
whichmay explain the much higher dropout ratein the prior
immunosuppressants group as shown in Table 2. If patients
undergo lengthy washout period rather than 7-day washouts
of prior immunosuppressants before initiating the herose
therapy, it may help the reduction of frequency and intensity
in wavelike ﬂare-up pattern as shown in Figure 3,b u ts u c h
a transition strategy may be not practical as it requires a
prolonged interval without therapy in psoriasis patients. In
generalpractice,physiciansmayprefertoinitiateanalternate
therapy within a short time frame or an overlapping of
therapies during transition to alternative.
4. Conclusions
The mechanism of action for clinical responses to herose, as
well as its ability to modulate pathologic cellular and inﬂam-
matory pathways in skin lesions, needs to be investigated
further, and this retrospective uncontrolled clinical obser-
vational study and previous clinical ﬁndings suggest that10 Dermatology Research and Practice
non-immunosuppressive approach may play an important
part in management of immune system cell (T cell) to avoid
misﬁring and inappropriately targeting the skin cells; it may
also be that pharmacogenomics is an important variable:
there may be groups of people who have a better response
to one or the other of therapeutic agents, perhaps because
of polymorphisms in genes that control the expression of
the relevant molecules. In our opinion, clinically useful
conclusionscanbedrawndespitethelimitationsofthisstudy
design, we suggest the non-immunosuppressive approach
may be used as the ﬁrst-line therapy to improve the thera-
peuticoutcomeinpatientswithpsoriasis,andfurtherclinical
investigation of controlled trial and mechanism of action is
needed to be conducted for this indication.
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